bs-0623R

[Primary Antibody]

Cyclin D1 Rabbit pAb




www.bioss.com.cn sales@bioss.com.cn techsupport@bioss.com.cn 400-901-9800

- DATASHEET		400-901-9800
Host: Rabbit Clonality: Polyclonal	Isotype: IgG	Applications: WB (1:500-2000) IHC-P (1:50-200)
GenelD: 595	SWISS: P24385	IHC-F (1:50-200) IF (1:50-200) ICC/IF (1:50-200)
Target: Cyclin D1		ICC/IF (1:50-200)
Immunogen: KLH conjugated synthetic peptide derived from human Cyclin D1: 61-110/295.		: Reactivity: Human, Mouse, Rat
Purification: affinity purified by	Protein A	
oncentration: 1mg/ml		Predicted
Storage: 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.		Predicted MW.: ^{32 kDa}
Shipped at 4°C. Ste freeze/thaw cycles	ore at -20°C for one year. Avoid repeated 5.	Subcellular Cell membrane ,Cytoplasm Location: ,Nucleus
cyclin family, whos periodicity in prote function as regulat distinct expression the temporal coord complex with and CDK6, whose activ protein has been s Rb and the express Mutations, amplific alters cell cycle pro	ed by this gene belongs to the highly conserver se members are characterized by a dramatic tin abundance throughout the cell cycle. Cyclin tors of CDK kinases. Different cyclins exhibit and degradation patterns which contribute to dination of each mitotic event. This cyclin forms functions as a regulatory subunit of CDK4 or ity is required for cell cycle G1/S transition. Thi hown to interact with tumor suppressor proteir sion of this gene is regulated positively by Rb. cation and overexpression of this gene, which ogression, are observed frequently in a variety pontribute to tumorigenesis. [provided by RefSer	s a s a of
- VALIDATION IMAGES —		
600 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 -		

15 -25 ug total protein per lane of various lysates (see on figure) probed with Cyclin D1 polyclonal antibody, unconjugated (bs-0623R) at 1:2000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at

- Cyclin D1



Paraformaldehyde-fixed, paraffin embedded Human Breast Cancer; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with Cyclin D1 Polyclonal Antibody, Unconjugated (bs-0623R) at 1:200 overnight at 4°C, followed by conjugation to the bs-0295G-HRP and DAB (C-0010) staining.



Paraformaldehyde-fixed, paraffin embedded Human Colon Cancer; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with Cyclin D1 Polyclonal Antibody, Unconjugated (bs-0623R) at 1:200 overnight at 4°C, followed by conjugation to the bs-0295G-HRP and DAB (C-0010) staining.

- SELECTED CITATIONS -

r.t. for 60 min.

- [IF=14.903] Luchen Sun. et al. A novel mesenchymal stem cell-based regimen for acute myeloid leukemia differentiation therapy. ACTA PHARM SIN B. 2023 May;: WB ;Human. 10.1016/j.apsb.2023.05.007
- [IF=13.273] Long Zhao. et al. Juglone-loaded metal-organic frameworks for H2O2 self-modulating enhancing chemodynamic therapy against prostate cancer. Chem Eng J. 2022 Feb;430:133057 WB ;Human. 10.1016/j.cej.2021.133057

- [IF=8.755] Sijie Wang. et al. PFKFB4 facilitates palbociclib resistance in oestrogen receptor-positive breast cancer by enhancing stemness. CELL PROLIFERAT. 2022 Sep;:e13337 WB ;Human. 36127291
- [IF=8.74] Chen et al. STAT1 inhibits human hepatocellular carcinoma cell growth through induction of p53 and Fbxw7. (2015) Cancer.Cell.Int. 15:111 WB ;Human. 26617467
- [IF=9.429] Li, Guang. et al. Synergetic delivery of artesunate and isosorbide 5-mononitrate with reduction-sensitive polymer nanoparticles for ovarian cancer chemotherapy. J NANOBIOTECHNOL. 2022 Dec;20(1):1-13 WB ;Human. 36335352